Merck & Co., Inc. (MRK)
| Market Cap | 358.41B +63.8% |
| Revenue (ttm) | 66.57B +4.6% |
| Net Income | 3.17B -80.7% |
| EPS | 1.27 -80.4% |
| Shares Out | 2.47B |
| PE Ratio | 114.13 |
| Forward PE | 17.47 |
| Dividend | $3.40 (2.34%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 8,381,069 |
| Open | 145.02 |
| Previous Close | 147.24 |
| Day's Range | 143.41 - 145.44 |
| 52-Week Range | 82.01 - 156.92 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 159.76 (+9.98%) |
| Earnings Date | Oct 29, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $159.76, which is an increase of 9.98% from the latest price.
News
Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful
Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the company's stock price and more.
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thurs...
Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
Moderna shares are taking a hit after the leak of highly anticipated details about the company's vaccine for the skin cancer melanoma.
Merck intismeran data concerns look ‘overdone,’ says Wells Fargo
After detailed data for the Phase 3 INTerpath-001 trial evaluating intismeran autogene in adjuvant melanoma was leaked, and then released by Merck (MRK) and Moderna (MRNA), Wells Fargo said the…
Merck, Moderna say INTerpath-001 trial data demonstrates favorable OS trend
Merck (MRK) and Moderna (MRNA) announced detailed positive recurrence-free survival and distant metastasis-free survival results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene, a ...
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence...
Moderna extends decline to 25%, Merck down 3% after alleged data leak
Shares of Moderna (MRNA) are down about 25% in afternoon trading while shares of partner Merck (MRK) are down 3% following the alleged leak of embargoed Phase 3 data for…
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Red...
Merck’s Keytruda plus Padcev approved by EC for treatment of MIBC
Merck (MRK) announced the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev, as neoadjuvant treatment and then continued after radical cystectomy as adju...
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck's ant...
Merck price target lowered to $155 from $160 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Merck (MRK) to $155 from $160 and keeps a Buy rating on the shares. Heading into Q3 results, Merck has continued to…
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Why Healthcare Stocks Are Hot When the AI Trade Runs Cold
Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.
The Big 3: MRK, GILD, XOM
The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a s...
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowledged that manufacturing the vaccine is a "complex sy...
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Merck announces Diaz to join Board of Directors
Merck (MRK) & Co. announced that Paul Diaz, managing partner at Cressey & Company, will join the Company’s Board of Directors effective Nov. 1, 2026. He will stand for election…
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
RAHWAY, N.J.--(BUSINESS WIRE)--Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors.
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be...
Merck price target lowered to $145 from $150 at RBC Capital
RBC Capital analyst Trung Huynh lowered the firm’s price target on Merck (MRK) to $145 from $150 and keeps a Sector Perform rating on the shares. The firm is reducing…
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase ...
Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.